Amylyx Pharmaceuticals IncNASDAQ:AMLX
- LAST PRICE4.7600
- TODAY'S CHANGE (%)-0.2600 (-5.1793%)
- Bid / Lots4.8500/ 1
- Ask / Lots4.9000/ 5
- Open / Previous Close4.9800 / 5.0200
- Day Range
- 52 Week Range
- Volume1,579,928
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMLX |
|---|---|---|
| 09:32 ET | 27323 | 4.975 |
| 09:33 ET | 1100 | 4.97 |
| 09:35 ET | 10909 | 5.01 |
| 09:37 ET | 3701 | 4.985 |
| 09:39 ET | 4583 | 4.96 |
| 09:42 ET | 3244 | 4.96 |
| 09:44 ET | 3312 | 4.96 |
| 09:46 ET | 6425 | 4.95 |
| 09:48 ET | 61658 | 4.885 |
| 09:50 ET | 23873 | 4.84 |
| 09:51 ET | 22215 | 4.8 |
| 09:53 ET | 5024 | 4.85 |
| 09:55 ET | 9238 | 4.865 |
| 09:57 ET | 14450 | 4.86 |
| 10:00 ET | 6360 | 4.84 |
| 10:02 ET | 1840 | 4.83 |
| 10:04 ET | 1793 | 4.77 |
| 10:06 ET | 6310 | 4.76 |
| 10:08 ET | 13072 | 4.72 |
| 10:09 ET | 30018 | 4.79 |
| 10:11 ET | 1874 | 4.7812 |
| 10:13 ET | 6346 | 4.79 |
| 10:15 ET | 6992 | 4.82 |
| 10:18 ET | 7213 | 4.8 |
| 10:20 ET | 2134 | 4.79 |
| 10:22 ET | 7767 | 4.74 |
| 10:24 ET | 4635 | 4.715 |
| 10:26 ET | 7255 | 4.695 |
| 10:27 ET | 9850 | 4.7109 |
| 10:29 ET | 14262 | 4.75 |
| 10:31 ET | 3014 | 4.75 |
| 10:33 ET | 1400 | 4.77 |
| 10:36 ET | 1513 | 4.77 |
| 10:38 ET | 1900 | 4.755 |
| 10:40 ET | 3468 | 4.785 |
| 10:42 ET | 2499 | 4.805 |
| 10:44 ET | 2462 | 4.79 |
| 10:45 ET | 9394 | 4.8 |
| 10:47 ET | 1907 | 4.805 |
| 10:49 ET | 5403 | 4.83 |
| 10:51 ET | 3551 | 4.835 |
| 10:54 ET | 2250 | 4.7991 |
| 10:56 ET | 1200 | 4.79 |
| 10:58 ET | 1494 | 4.785 |
| 11:00 ET | 7962 | 4.83 |
| 11:02 ET | 22656 | 4.79 |
| 11:03 ET | 4729 | 4.76 |
| 11:05 ET | 200 | 4.76 |
| 11:07 ET | 2824 | 4.76 |
| 11:09 ET | 1756 | 4.75 |
| 11:12 ET | 4568 | 4.735 |
| 11:14 ET | 3912 | 4.705 |
| 11:16 ET | 4252 | 4.72 |
| 11:18 ET | 1682 | 4.715 |
| 11:20 ET | 1920 | 4.695 |
| 11:21 ET | 30568 | 4.695 |
| 11:23 ET | 4534 | 4.69252 |
| 11:25 ET | 3016 | 4.68 |
| 11:27 ET | 8681 | 4.645 |
| 11:30 ET | 2768 | 4.645 |
| 11:32 ET | 3657 | 4.655 |
| 11:34 ET | 2196 | 4.6402 |
| 11:36 ET | 2927 | 4.65 |
| 11:38 ET | 8313 | 4.65 |
| 11:39 ET | 5837 | 4.635 |
| 11:41 ET | 2824 | 4.635 |
| 11:43 ET | 9608 | 4.675 |
| 11:45 ET | 1319 | 4.685 |
| 11:48 ET | 6767 | 4.71 |
| 11:50 ET | 756 | 4.705 |
| 11:52 ET | 648 | 4.7 |
| 11:54 ET | 4247 | 4.695 |
| 11:56 ET | 5706 | 4.68 |
| 11:57 ET | 5482 | 4.68 |
| 11:59 ET | 7291 | 4.695 |
| 12:01 ET | 6938 | 4.6917 |
| 12:03 ET | 11288 | 4.645 |
| 12:06 ET | 6375 | 4.63 |
| 12:08 ET | 14280 | 4.6 |
| 12:10 ET | 2382 | 4.59 |
| 12:12 ET | 6072 | 4.5912 |
| 12:14 ET | 10625 | 4.635 |
| 12:15 ET | 2576 | 4.63 |
| 12:17 ET | 1717 | 4.635 |
| 12:19 ET | 4687 | 4.675 |
| 12:21 ET | 1302 | 4.67 |
| 12:24 ET | 2026 | 4.65 |
| 12:26 ET | 1673 | 4.65 |
| 12:28 ET | 500 | 4.655 |
| 12:30 ET | 586 | 4.66 |
| 12:32 ET | 4312 | 4.645 |
| 12:33 ET | 600 | 4.645 |
| 12:35 ET | 683 | 4.645 |
| 12:37 ET | 9492 | 4.6312 |
| 12:39 ET | 2642 | 4.65 |
| 12:42 ET | 1090 | 4.645 |
| 12:44 ET | 1907 | 4.645 |
| 12:46 ET | 1264 | 4.64 |
| 12:48 ET | 2600 | 4.64 |
| 12:50 ET | 16270 | 4.655 |
| 12:51 ET | 3520 | 4.651 |
| 12:53 ET | 1944 | 4.64 |
| 12:55 ET | 1110 | 4.645 |
| 12:57 ET | 324 | 4.6412 |
| 01:00 ET | 4069 | 4.645 |
| 01:02 ET | 1126 | 4.645 |
| 01:04 ET | 1450 | 4.645 |
| 01:06 ET | 609 | 4.645 |
| 01:08 ET | 1195 | 4.645 |
| 01:09 ET | 7139 | 4.645 |
| 01:11 ET | 2526 | 4.64 |
| 01:13 ET | 2533 | 4.625 |
| 01:15 ET | 1300 | 4.65 |
| 01:18 ET | 2574 | 4.6407 |
| 01:20 ET | 2200 | 4.66 |
| 01:22 ET | 1390 | 4.64 |
| 01:24 ET | 373 | 4.645 |
| 01:26 ET | 900 | 4.65 |
| 01:27 ET | 700 | 4.645 |
| 01:29 ET | 732 | 4.66 |
| 01:31 ET | 600 | 4.655 |
| 01:33 ET | 816 | 4.6547 |
| 01:36 ET | 9682 | 4.65 |
| 01:38 ET | 2267 | 4.64 |
| 01:40 ET | 2972 | 4.64 |
| 01:42 ET | 4363 | 4.615 |
| 01:44 ET | 1866 | 4.6088 |
| 01:45 ET | 2281 | 4.615 |
| 01:47 ET | 3391 | 4.61 |
| 01:49 ET | 9368 | 4.58 |
| 01:51 ET | 1768 | 4.585 |
| 01:54 ET | 1331 | 4.6 |
| 01:56 ET | 1425 | 4.6 |
| 01:58 ET | 3456 | 4.61 |
| 02:00 ET | 2907 | 4.62 |
| 02:02 ET | 5900 | 4.625 |
| 02:03 ET | 2727 | 4.62 |
| 02:05 ET | 2846 | 4.6183 |
| 02:07 ET | 337 | 4.61 |
| 02:09 ET | 2912 | 4.615 |
| 02:12 ET | 100 | 4.62 |
| 02:14 ET | 100 | 4.61 |
| 02:16 ET | 1097 | 4.61 |
| 02:18 ET | 7114 | 4.6292 |
| 02:20 ET | 2984 | 4.62 |
| 02:21 ET | 200 | 4.625 |
| 02:23 ET | 4945 | 4.635 |
| 02:25 ET | 2588 | 4.635 |
| 02:27 ET | 1364 | 4.635 |
| 02:30 ET | 3455 | 4.645 |
| 02:32 ET | 574 | 4.645 |
| 02:34 ET | 1226 | 4.65 |
| 02:36 ET | 5779 | 4.67 |
| 02:38 ET | 3580 | 4.645 |
| 02:39 ET | 574 | 4.645 |
| 02:41 ET | 1436 | 4.66 |
| 02:43 ET | 4677 | 4.665 |
| 02:45 ET | 13417 | 4.685 |
| 03:14 ET | 199 | 4.7 |
| 03:15 ET | 9444 | 4.685 |
| 03:17 ET | 21750 | 4.685 |
| 03:19 ET | 700 | 4.68 |
| 03:21 ET | 2267 | 4.685 |
| 03:24 ET | 15254 | 4.68 |
| 03:26 ET | 7025 | 4.685 |
| 03:28 ET | 12043 | 4.68 |
| 03:30 ET | 1000 | 4.68 |
| 03:32 ET | 1236 | 4.6875 |
| 03:33 ET | 18154 | 4.68 |
| 03:35 ET | 3543 | 4.69 |
| 03:37 ET | 3284 | 4.695 |
| 03:39 ET | 18409 | 4.695 |
| 03:42 ET | 27786 | 4.725 |
| 03:44 ET | 6758 | 4.715 |
| 03:46 ET | 43484 | 4.715 |
| 03:48 ET | 2463 | 4.715 |
| 03:50 ET | 28778 | 4.76 |
| 03:51 ET | 19941 | 4.75 |
| 03:53 ET | 29081 | 4.75 |
| 03:55 ET | 28539 | 4.755 |
| 03:57 ET | 24614 | 4.76 |
| 04:00 ET | 134640 | 4.76 |
Nov 8, 2024
DJ Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 7:46AM ET on Friday Nov 08, 2024 by Dow Jones
7:46AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Press Release: Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow JonesAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
Press Release: Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024, from 9:04AM ET on Monday Nov 04, 2024 by Dow Jones
9:04AM ET on Monday Nov 04, 2024 by Dow JonesAmylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024, from 9:00AM ET on Monday Nov 04, 2024 by Dow Jones
9:00AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amylyx Pharmaceuticals Inc | 324.1M | -1.2x | --- |
Organogenesis Holdings Inc | 511.7M | -68.1x | --- |
Amarin Corporation PLC | 205.7M | -5.2x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Ironwood Pharmaceuticals Inc | 672.5M | -262.8x | --- |
Ginkgo Bioworks Holdings Inc | 334.9M | -0.5x | --- |
Company Information
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Contact Information
- Headquarters
- 43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141
- Phone
- 617-682-0917
- Fax
- 302-636-5454
Executives
- Chair of the Board of Directors
- George Milne
- Co-Chief Executive Officer, Director
- Joshua Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Chief Financial Officer
- James Frates
- Chief Legal Officer and General Counsel
- Gina Mazzariello
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $324.1M |
|---|---|
Revenue (TTM) | $196.5M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.82 |
Book Value | $6.40 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -138.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
